PRKN and Parkinson disease: Our lab and collaborators recently elucidated the mechanism of the Biogen activators, and discovered that they act like molecular glue to bridge Parkin with pUb at the site where phospho-Ubl binds, thus enabling the rescue of Parkinson’s mutation in the Ubl domain (149).